gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ORGOHealthcarePharmaceuticals

Organogenesis Holdings Inc. Class A Common Stock (ORGO)

$0.8700+4.19%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$0.87▼ 77.58% in range
Nov 4, 2025Low $0.76 · High $6.54Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Organogenesis Holdings closed at $0.87 on Nov 4, up 4.19%, 86.7% below its 52-week closing high. Volume of 738.1K shares was 0.69× its 20-day average (below normal).

Split-adjusted performance: -35.1% over one month, -66.0% over six months, -78.2% over one year.

In the quarter ended Jun 30, 2026, revenue was $43.76M, down 56.7% from a year earlier, with a net margin of -227.0%.

Short interest was 15.6M shares at the Oct 15 settlement, up 3.9% from the prior report (21.7% of float, 21.2 days to cover).

Market cap$111.9M128.7M shares
Revenue · quarter$43.8M−56.7% YoY
Diluted EPS$-0.77—
P/E · TTM—P/S 0.2×
Net margin-227.0%Gross 100.0%
Dividend yieldNone
52-week range0.76 – 6.54−86.7% from high
Volume738.1K0.69× 20-day avg
Volatility · 60d61.2%Annualised
Short % of float21.7%21.2 days to cover
Net cash$34.4MCash $46.1M
Next earnings—Not scheduled
Split-adjusted performance
1W +5.5%1M −35.1%3M −63.9%6M −66.0%YTD −83.2%1Y −78.3%3Y −60.6%5Y −91.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum15
Revenue growth20
Net margin34
Value (low P/E)—
Size42

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short15.6M+3.9% vs prior
Days to cover21.2Settled Oct 15
% of float21.7%
Short vol. 10d56.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ORGOOrganogenesis Holdings$0.8700+4.19%−66.0%−56.7%−227.0%—$111.9M
ANIXAnixa Biosciences$3.28+7.37%+7.2%———$114.0MCompare
EQEquillium$1.40−0.71%−35.5%———$109.7MCompare
HURATuHURA Biosciences$1.72+3.93%−32.3%———$109.6MCompare
IMUXImmunic$7.94+4.47%−27.9%———$108.3MCompare
NRXPNRX Pharmaceuticals$2.49+11.16%−18.4%—−1500.5%—$107.8MCompare
OKUROnKure Therapeutics$2.59+3.60%−36.4%———$104.9MCompare
UNCYUnicycive Therapeutics$3.75+4.46%−53.9%———$104.5MCompare
NERVMinerva Neurosciences$2.57+9.36%−58.7%———$122.7MCompare

News about Organogenesis Holdings

All news →
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AMGlobeNewswire Inc. · Apr 6, 2026▲ Positive

Quick answers

What does Organogenesis Holdings do?
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting.
What is ORGO's market cap?
$111.95M, based on the Nov 4 close of $0.87.
Does Organogenesis Holdings pay a dividend?
No regular cash dividend has been paid in the last year.
How much of ORGO is sold short?
15.6M shares, 21.7% of float, as of Oct 15, 2026.
What sector is ORGO in?
Healthcare, in the Pharmaceuticals industry.

About Organogenesis Holdings

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.

HQ: Canton, MA854 employeesListed Nov 29, 2016organogenesis.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology